Elotuzumab for Myelofibrosis
Trial Summary
What is the purpose of this trial?
This phase II trial investigates how well elotuzumab works in treating patients with JAK2-mutated myelofibrosis. Elotuzumab may help to control myelofibrosis and/or help to improve blood cell count and bone marrow function.
Will I have to stop taking my current medications?
The trial requires that you stop taking certain medications like chemotherapy (except hydroxyurea), interferons, and other specific treatments for myelofibrosis at least 4 weeks before joining. If you're on other investigational drugs, you need to stop them for a period based on their half-lives before starting the trial.
Is Elotuzumab safe for humans?
Elotuzumab, also known as Empliciti, has been used to treat multiple myeloma, and while specific safety data for myelofibrosis is not available, it has been studied for its potential to target certain cells in myelofibrosis. Generally, it is important to consult with healthcare providers for detailed safety information.12345
How does the drug Elotuzumab differ from other treatments for myelofibrosis?
Elotuzumab is unique because it targets SLAMF7, a protein highly expressed on fibrocytes involved in myelofibrosis, and inhibits their differentiation, which is not a mechanism used by other treatments like JAK inhibitors. This approach could be particularly beneficial for patients with the JAK2V617F mutation, offering a novel way to address the disease.25678
Research Team
Prithviraj Bose
Principal Investigator
M.D. Anderson Cancer Center
Eligibility Criteria
Adults with JAK2 V617F+ myelofibrosis needing treatment and at intermediate/high risk. They must have good performance status, specific blood counts, liver and kidney function levels, agree to use contraception, and not be candidates for JAK inhibitor therapy. Excluded are those recently on certain treatments or with allergies to similar drugs, CNS involvement, uncontrolled illnesses, pregnancy/lactation, HIV/HBV/HCV positivity or prior transplants.Inclusion Criteria
Exclusion Criteria
Timeline
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive elotuzumab intravenously over 1-4 hours on days 1, 8, 15, and 22 of cycles 1-2, and on day 1 from cycle 3 onwards. Treatment repeats every 28 days for up to 36 cycles.
Follow-up
Participants are monitored for safety and effectiveness after treatment completion, with follow-up at 30 days and periodically thereafter.
Treatment Details
Interventions
- Elotuzumab
Elotuzumab is already approved in United States, European Union, Canada for the following indications:
- Multiple myeloma
- Multiple myeloma
- Multiple myeloma
Find a Clinic Near You
Who Is Running the Clinical Trial?
M.D. Anderson Cancer Center
Lead Sponsor